Member Info for BuenaVista

Just a reminder that wyndrum isn't invested - and is only here to disrupt and and sow discord.

Just a reminder that wyndrum isn't invested.

They'll be buying US oil stocks you mean.

Well let's hope she reads this and uses an egg and some wipes next time.

The FDA's ODD was for STS.

Absolutely VS. Granted US patent valid until 15 June 2035, filed when AVA6000 was called 3099DOX: https://patents.google.com/patent/US9737556B2/en

PDF of the US patent: https://patentimages.storage.googleapis.com/9e/f0/c7/8edbda02211a3e/US9737556.pdf

The Written Opinion reduced the claims to "The subject-matter of claims 48-50 and 87 therefore meet the requirements of the PCT with respect to novelty and inventive step."

48. The compound of claim 1, wherein the compound is selected from those in Table 4, and pharmaceutically acceptable salts thereof.

49. A compound, wherein the compound is selected from those in Table 5B, and pharmaceutically acceptable salts thereof.

50. A construct, or a pharmaceutically acceptable salt thereof, comprising a compound selected from those in Table 5B, or a pharmaceutically acceptable salt thereof, conjugated to a binding moiety.

87. The construct of claim 11, wherein the construct is selected from those in Table 5A.

- - - - -

Here's hoping that AVA6103 is amongst these allowed compounds! It is normal to make very broad claims as well as for what you want to specifically cover. The broader the claims that are accepted, the better the protection, but it's usual for many of them to be rejected. That's not such a bad thing - and is integral to why broad claims are made - as all the compounds described in the application, whether ultimately allowed or not, are now in the public domain and so have lost 'novelty', which will therefore bar other companies from working in those areas.

- - - - -

Who'd be a patent agent, patent examiner, or patent attorney, eh?!

Is Unicorno HurstBot with an inbuilt AI module?

Unicorno's AI wrote: "The publication of this patent on January 2nd is a clear tactical signal. ... With exactly 10 days until the J.P. Morgan Healthcare Conference begins on January 12th, Avacta has presented the market (and potential partners) with the final legal proof they need to sign a binding offer."

This implies that Avacta dictated when the World Intellectual Property Organisation should publish the patent.

🤣🤣🤣

No, what I actually wrote - and I will put it in quotes, like how you misquoted me - was "Note that the patents published today are patent applications, not legally enforceable granted patents."

If you want some real FUD, I would hazard a guess that no company would enter an agreement with Avacta based just on patent applications without the surety of having the invention(s) fully protected by granted IP. It will take a while for the patent applications to be examined and potentially challenged - there is always the provision for that to be done prior to granting a patent. Of course, clauses could be written into any agreement that would up the value if/when IP protection is granted.

https://www.google.com/search?q=can+a+patent+application+be+challenged+before+granting

Just a reminder that Thornogson/NDN/Eggy isn't invested and works for Tom Winnifrith.

Re "By securing this patent, Avacta has legally locked down the ability to deliver Exatecan—the same high-potency payload used in blockbuster drugs like Enhertu—using their safe, tumor-targeted "masking" system. This patent allows Avacta to expand from SGC and Sarcoma into massive "blockbuster" markets like Pancreatic, Gastric, and Triple Negative Breast Cancer (TNBC), which are highly sensitive to Topo inhibitors."

Note that the patents published today are patent applications, not legally enforceable granted patents.

WO2026002995 - Target-Specific FAP-Activated Topoisomerase Inhibitor Conjugates And Uses Thereof

Inventors: WILSON, Francis, WATTS, Ellen, CLOUGH, Thomas, JONES, David, SPENCE, Graham Robert Pye-Smith, JUSKAITE, Victoria, PINTO, Manuel, SAMMON, Douglas, EDWARDS, Ruairidh, BUIST, Hanna

Abstract: (EN) Provided herein are compounds, including compounds of Formula (I') and (I), and pharmaceutically acceptable salts thereof, and constructs, including constructs of Formula (II') and (II), and pharmaceutically acceptable salts thereof, which comprise a fibroblast activating protein (FAP)-cleavable moiety and are capable of delivering a camptothecin to FAP-expressing tissues (e.g., cancers). Also provided herein are pharmaceutical compositions and kits comprising the same, as well as methods of using the same. [Note by BV: exatecan is a camptothecin]

BACKGROUND

Prodrugs that can be specifically activated within the tumor microenvironment offer a powerful approach to cancer therapy by providing enhanced selectivity and reducing off-target effects. These prodrugs remain inert in the body until they encounter the unique physiological conditions of the tumor, such as acidic pH, high enzymatic activity, or specific reductive environments. This targeted activation ensures that the therapeutic agent is released directly at the tumor site, minimizing damage to healthy tissues and reducing systemic toxicity. Moreover, tumor-specific activation can improve drug efficacy, as the active form of the drug is concentrated where it is most needed, potentially allowing for higher doses to be used safely. This strategy enhances treatment precision and can overcome some of the challenges associated with traditional chemotherapy.

SUMMARY

[4] Provided herein are compounds and constructs comprising a fibroblast activating protein (FAP)-cleavable moiety that are capable of delivering a camptothecin to FAP-expressing tissues (e.g., cancers). Also provided herein are pharmaceutical compositions comprising the constructs provided herein, and kits comprising the same.

[continues]

WO2026002988 - Fibroblast Activation Protein Alpha Binder Proteins

Inventors: JONES, David, SPENCE, Graham Robert Pye-Smith, JUSKAITE, Victoria, PINTO, Manuel, SAMMON, Douglas, EDWARDS, Ruairidh, BUIST, Hanna

Abstract: (EN) The technology relates to polypeptides comprising a scaffold comprising a sequence having at least 90% identity to the amino acid sequence of human Stefin A, wherein the scaffold sequence includes (a) an insertion of an amino acid between amino acid positions corresponding to M1 and I2 of the amino acid sequence of human Stefin A and (b) a mutation at an amino acid position corresponding to N32 of the amino acid sequence of human Stefin A, and a heterologous peptide. The technology also relates to human Stefin A variants that bind to fibroblast activation protein alpha and/or human serum albumin.

BACKGROUND

[3] AFFIMER® proteins are small, engineered proteins based on human Stefin A that bind to specific target molecules with high affinity and specificity. They are part of a class of binding proteins known as alternative scaffolds or non-antibody binding proteins. AFFIMER® proteins offer several advantages over other binder proteins, such as antibodies, including size and stability, ease of production, versatility, customizability, and lack of post-translational modification.

[4] AFFIMER® proteins are smaller and often more stable than antibodies, making them easier to produce and manipulate in various experimental conditions. AFFIMER® proteins can be produced in large quantities using bacterial expression systems, for example, which is often more cost-effective and scalable than antibody production. AFFIMER® proteins can be engineered to bind a wide range of targets, including proteins, small molecules, and even cells. Their binding characteristics can be finetuned through protein engineering, allowing for the development of highly specific reagents for research, diagnostic, and therapeutic applications. Lastly, unlike antibodies, AFFIMER® proteins do not require post-translational modifications, simplifying their production.

SUMMARY

[5] Provided herein, in some aspects, are polypeptide scaffolds, for example, AFFIMER® polypeptide scaffolds, based on variants of human Stefin A, which include modification(s) that prevent amino terminal acetylation/oxidation and increase thermal stability, relative to the naturally occurring human Stefin A protein. Thus, the polypeptide scaffolds provided herein are designed to exhibit improved stability, binding affinity, and manufacturability, relative to other polypeptide scaffolds based on variants of human Stefin A.

[continues]

Excellent stuff!

I hope Avacta are pricing any deals in GBP.

Thornogson/NDN/Eggy can't keep track of his - or her - own lies.

.

Just a reminder that Toukankahmoon is angry because he got spiked, twice.

Just a reminder that Thornogson/NDN/|Eggy isn't invested and works for Tom Winnifrith.